Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine + Dolutegravir Dual Therapy Switch in HIV
NCT04892654Phase 3Recruiting
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Aug 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doravirine and dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Percentage of Participants with undetectable plasma HIV RNA levels at 48 weeks. Started Aug 2022; status: recruiting.
02
Drugs
doravirinedolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04892654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892654.